Biohaven Pharmaceutical Holding EBITDA 2016-2022 | BHVN

Biohaven Pharmaceutical Holding annual and quarterly EBITDA history from 2016 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Biohaven Pharmaceutical Holding EBITDA for the quarter ending March 31, 2022 was $-0.049B, a 78.57% decline year-over-year.
  • Biohaven Pharmaceutical Holding EBITDA for the twelve months ending March 31, 2022 was $-0.498B, a 30.44% decline year-over-year.
  • Biohaven Pharmaceutical Holding 2021 annual EBITDA was $-0.679B, a 6.79% increase from 2020.
  • Biohaven Pharmaceutical Holding 2020 annual EBITDA was $-0.636B, a 32.91% increase from 2019.
  • Biohaven Pharmaceutical Holding 2019 annual EBITDA was $-0.478B, a 117.29% increase from 2018.
Biohaven Pharmaceutical Holding Annual EBITDA
(Millions of US $)
2021 $-679
2020 $-636
2019 $-478
2018 $-220
2017 $-108
2016 $-61
2015 $-10
Biohaven Pharmaceutical Holding Quarterly EBITDA
(Millions of US $)
2022-03-31 $-49
2021-12-31 $-149
2021-09-30 $-134
2021-06-30 $-166
2021-03-31 $-231
2020-12-31 $-166
2020-09-30 $-160
2020-06-30 $-159
2020-03-31 $-151
2019-12-31 $-135
2019-09-30 $-90
2019-06-30 $-199
2019-03-31 $-54
2018-12-31 $-48
2018-09-30 $-55
2018-06-30 $-38
2018-03-31 $-83
2017-12-31 $-28
2017-09-30 $-40
2017-06-30 $-25
2017-03-31 $-14
2016-12-31 $-23
2016-09-30 $-28
2016-06-30 $-7
2016-03-31 $-3
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.057B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00